EU GLP-1 regulations: why compounding is banned, what coverage looks like
The European Medicines Agency takes a stricter line than the FDA. Compounded semaglutide is illegal across all EU member states. Weight-loss reimbursement varies — most countries cover diabetes, very few cover obesity. Here’s the country-by-country picture.
The compounding ban — in plain language
Semaglutide is a centrally authorized medicinal product in the EU — meaning the European Medicines Agency, not individual member states, controls the Marketing Authorization. Novo Nordisk holds that authorization exclusively for Ozempic, Wegovy, and Rybelsus formulations.
EU compounding law (Directive 2001/83/EC, Article 5) allows pharmacy preparation only when an authorized product cannot meet an individual patient’s medical need. Cost is not a permitted reason. A pharmacist who prepares semaglutide outside a per-patient medical necessity faces criminal exposure under Article 86 of the Falsified Medicines Directive.
In 2024-2025, regulators in Germany (BfArM), Netherlands (CBG-MEB), Sweden (Läkemedelsverket), and Ireland (HPRA) have all issued enforcement actions against pharmacies and online operators marketing compounded semaglutide. The MHRA UK has acted similarly. Cross-border sale from a non-EU operator (e.g., a US compounder) into the EU is also prohibited.
EU country-by-country: who pays what
| Country | Weight loss | Diabetes | Retail cash |
|---|---|---|---|
| 🇩🇪Germany | Not covered (Lifestyle-Arzneimittel) | GKV covered | €140-180/mo |
| 🇫🇷France | Not covered (Sécurité sociale) | Covered, ALD30 | €175-220/mo |
| 🇮🇹Italy | Not covered (Lega 326) | SSN regional formularies | €155-205/mo |
| 🇪🇸Spain | Not covered (SNS) | Covered for T2D with BMI ≥35 | €140-190/mo |
| 🇳🇱Netherlands | Limited (Vergoeding Centraal Beheer) | Basic insurance covers diabetes | €170-210/mo |
| 🇸🇪Sweden | Not covered | High-cost protection (Högkostnadsskydd) | €170-230/mo |
| 🇮🇪Ireland | Not covered (HSE) | Covered under DPS | €175-240/mo |
What’s illegal in the EU
- Selling compounded semaglutide for cost reasons — Article 5 of 2001/83/EC permits only for individual medical necessity.
- Importing "research peptide" semaglutide for personal injection use.
- Cross-border telehealth from non-EU prescribers issuing EU-shippable semaglutide prescriptions.
- Selling Wegovy or Mounjaro without a valid EU prescription.
Legal access routes
- 1. Public-sector route — speak to your GP or specialist. Diabetes is broadly covered; weight loss usually is not.
- 2. Private telehealth — Eucalyptus (Pilot, Juniper for UK and EU rollouts), Heynow Germany, country-specific operators.
- 3. Private clinic — endocrinologist or obesity-medicine specialist. Cost €185-280/mo plus consult fees.
- 4. Cross-border in EU — Schengen allows you to fill a private prescription in another EU member state with lower retail cost (Germany has lowest at €140-180/mo).
FAQ
Why is compounded semaglutide prohibited in the EU?
Under EMA centralized authorization, semaglutide is a centrally authorized medicinal product (Marketing Authorization granted to Novo Nordisk). EU compounding rules (Directive 2001/83/EC, Article 5) permit pharmacy preparation only for an individual patient with a medical need that cannot be met by the authorized product. Compounding for cost reasons — the common US justification — is explicitly excluded. Bulk-prepared semaglutide for sale is treated as unlicensed manufacture and falls under Article 86 of the Falsified Medicines Directive. Several EU member states (Germany, Netherlands) have prosecuted operators in 2024-2025.
Are there any EU telehealth providers offering legal GLP-1 prescriptions?
Yes, in countries where private prescriptions are permitted: Eucalyptus (Pilot, Juniper), Numan UK (technically outside EU), Form Health partners, and country-specific operators like Heynow (Germany), Care/of (Netherlands). All operate under MHRA/EMA-equivalent licensing. They prescribe authorized branded semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), not compounds. Cash retail through these channels: €185-280/month depending on country.
What about grey-market "research peptides" sold online as semaglutide?
These are illegal under EU law. They are not the same as compounded semaglutide — they are unlicensed bulk peptide sold under the label "research use only" with no clinical validation, no cold-chain handling, and frequently sub-therapeutic or contaminated. The MHRA, BfArM (Germany), and ANSM (France) have all issued enforcement actions in 2024-2025. Importation for personal use is also prohibited; customs seizures have been documented at Heathrow, Frankfurt, and Schiphol.
If I move from the EU to the US, can I bring my prescription?
A valid EU prescription is not directly transferable to a US pharmacy. You will need a US-licensed prescriber to issue a new prescription. However, US telehealth providers (Ro, Hims, Found, Sequence) typically accept prior treatment history at intake — bringing your EU prescription and clinical records to your first US consultation speeds the new prescription process. Inverse direction (US to EU) is significantly harder — most EU prescribers will not transfer a US-issued prescription without independent clinical evaluation.